论文部分内容阅读
将垂体催乳素瘤和高催乳素血症41例,经测定血清催乳素(PRL)值.结合CT及/或MRI检查后分为垂体巨腺瘤组、垂体微腺瘤组和特发性高催乳素血症组.8例巨腺癌及4例微腺瘤患者曾被施行手术或加放疗.全部病例口服溴隐亭并长期随访(平均31.1±19.1月).结果:月经恢复率为86.5%,妊娠率达70.8%.微腺瘤组和特发性高催乳素血症组的疗效比巨腺瘤组显著(P<0.05).单用溴隐亭者性腺功能恢复更好(P<0.05),部分病例还有肿瘤缩小的征象.研究结果提示服用溴隐亭是无压迫症状的垂体催乳素腺瘤的首选治疗手段.
Pituitary prolactinoma and hyperprolactinemia were determined in 41 cases and serum prolactin (PRL) values were determined. Combined with CT and/or MRI examination, they were divided into pituitary macroadenomas, pituitary microadenomas, and idiopathic highs. Patients with prolactinemia, 8 patients with macroadenocarcinoma and 4 patients with microadenomas were treated with surgery or radiotherapy. All patients were given oral bromocriptine and followed up for a long time (mean, 31.1±19.1 months). Results: The menstrual recovery rate was 86.5. %, The pregnancy rate was 70.8%. The efficacy of the microadenomas and idiopathic hyperprolactinemia groups was significantly greater than that of the giant adenomas group (P<0.05). The gonadotrophin function recovery was better with bromocriptine alone (P< 0.05), there are signs of tumor shrinkage in some cases. The results suggest that taking bromocriptine is the preferred treatment of pituitary prolactinoma without compression symptoms.